2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Interventions
rozanolixizumab
11
efgartigimod alfa
10
zilucoplan
8
Prednisone
8
Cyclophosphamide
8
ravulizumab
7
Rituximab
7
Pyridostigmine Bromide
7
telitacicept
6
fludarabine
6
Tacrolimus
6
Mycophenolic Acid
6
eculizumab
5
Immunoglobulins, Intravenous
5
Hizentra
4
Azathioprine
4
Steroids
3
HBM9161
3
Data Collection
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Thymectomy
2
Prednisolone
2
Methylprednisolone
2
Methotrexate
2
Exercise
2
Diagnostic Self Evaluation
2
Blood Specimen Collection
2
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
remibrutinib
×
Clear all
NCT06744920
2026-06-01
RELIEVE
Novartis
Phase 3
Recruiting
180 enrolled